Nuvation Bio (NUVB) announced that taletrectinib has been added as a preferred agent in the latest National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancers, updated on June 20. Specifically, the NCCN Guidelines now include taletrectinib as a preferred agent for both first-line and subsequent therapy for ROS1-positive NSCLC, including specific recommendations for those with brain metastases and resistance mutations.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB:
- Nuvation Bio price target lowered to $6 from $10 at RBC Capital
- Buy Rating for Nuvation Bio’s IBTROZI: FDA Approval and Competitive Edge in ROS1+ NSCLC Treatment
- Nuvation Bio’s IBTROZI Receives FDA Approval
- Nuvation Bio down 9% after FDA approves Ibtrozi
- Warnings for Nuvation’s Ibtrozi as expected, says JonesResearch